Design and Characterization of Baricitinib Incorporated PLA 3D Printed Pills by Fused Deposition Modeling for Treating Alopecia Areata

April 2023 in “ Polymers ”

Mohammed Muqtader Ahmed, Farhat Fatima, Aisha Alnami, Mohammad A. Alsenaidy, Alhussain Aodah, Mohammed F. Aldawsari, Bjad K. Almutairy, Md. Khalid Anwer, Mohammed Jafar

baricitinib alopecia areata fused deposition modeling polylactic acid PLA 3D-printed pills Korsmeyer-Peppas model JAK inhibitor BAB 3DP1 3DP2

From the encyclopedia

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This study developed and characterized 3D-printed pills incorporating Baricitinib (BAB) using polylactic acid (PLA) filaments through fused deposition modeling (FDM) to treat alopecia areata (AA). The pills, designed with a central hole to enhance drug release, were tested for drug encapsulation, release properties, and stability. Results showed drug release rates of 43.76% and 59.14% over 24 hours for 2% and 4% BAB concentrations, respectively, following the Korsmeyer–Peppas model. The study concluded that these 3D-printed pills could effectively deliver BAB with improved bioavailability and sustained release, offering a low-cost, personalized treatment option for AA.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

research The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care

117 citations , July 2021 in “British Journal of Dermatology”

This study reports that the incidence of alopecia areata is 0.26 per 1000 person-years in the UK, with higher rates among Asian ethnic groups, socially deprived populations, and urban residents.

research Alopecia Areata: An Autoimmune Disease of Multiple Players

31 citations , July 2021 in “ImmunoTargets and therapy”

This review compiles current evidence on the molecular mechanisms, etiologies, and targeted immunotherapies for alopecia areata and reports no new experimental results, emphasizing the need for further research to manage the disease.

research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata

40 citations , June 2021 in “Clinical, cosmetic and investigational dermatology”

This review explores the efficacy and outcomes of using JAK inhibitors for treating alopecia areata, noting advancements in understanding the disease's pathomechanisms and suggesting that JAK inhibitors may offer targeted therapeutic benefits by blocking specific inflammatory pathways involved in this chronic condition.

research Immunology of Alopecia Areata

23 citations , November 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology”

This review explores the autoimmune hypothesis of alopecia areata and the possible genetic and melanogenesis-associated autoantigens, but reports no new clinical findings.

research The Role of Family History and Its Influence on the Onset Time in Female Pattern Hair Loss

1 citations , January 2020 in “Postepy Dermatologii I Alergologii”

This study found that a positive family history, especially from the mother's side and including grandparents, is associated with an increased risk of early-onset female pattern hair loss in Polish women.

research Minoxidil And Its Use In Hair Disorders: A Review

117 citations , August 2019 in “Drug Design Development and Therapy”

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations , July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.

research Alopecia Areata: Part 2: Treatment

14 citations , September 2015 in “PubMed”

This review discusses treatment strategies for alopecia areata and emphasizes the importance of primary care physicians recognizing and managing the condition, with referrals to dermatologists for more severe cases.

research Epidemiology and Burden of Alopecia Areata: A Systematic Review

144 citations , July 2015 in “Clinical, Cosmetic and Investigational Dermatology”

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

research Alopecia Areata: A New Treatment Plan

67 citations , July 2011 in “Clinical, cosmetic and investigational dermatology”

This review discusses various therapeutic agents for alopecia areata, categorized by efficacy and safety, and highlights the lack of curative treatments and long-term outcome studies.